
REFERENCES

- Abel, E. (1980). *Marihuana [sic]: The first twelve thousand years*. New York, NY: Springer.
- Abrams, D. (2016). Using medical cannabis in an oncology practice. *Oncology*, *30*(5), 397-404.
- Adejumo, A.C., Alliu, S., Ajayi, T.O., Adejumo, K.L., Adegbala, O.M., Onyeakusi, N.E., Akinjero, A.M., Durojaiye, M., & Bukong, T.N. (2017). Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. *PLoS One*, *12*(4):e0176416.
- Agrawal, A., & Lynskey, M. (2013). Cannabis controversies: How genetics can inform the study of comorbidity. *Addiction*, *109*(3), 360-370.
- Aminoshariae, A., Kulild, J.C., Donaldson, M., & Hersch, E. (2016) Evidence-based recommendations for analgesic efficacy to treat pain of endodontic origin: a systematic review of randomized controlled trials. *Journal of the American Dental Association*, *147*(10), 826-839.
- Annas, G.J. (1997). Reefer madness--the federal response to California's medical-marijuana law. *New England Journal of Medicine*, *337*(6), 435-9.
- Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., ... Rahman, M. (2008). Antibacterial cannabinoids from *Cannabis sativa*: A structure-activity study. *Journal of Natural Products*, *71*(8), 1427-1430.
- Auther, A.M., Cadenhead, K.S., Carrión, R.E., Addington, J., Bearden, C.E., Cannon, T.D., McGlashan, T.H., Perkins, D.O., Seidman, L., & Tsuang, M. (2015). Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. *Acta Psychiatrica Scandinavica*, *132*(1), 60-8.

- Bagot, K., Milin, R., & Kaminer, Y. (2015). Adolescent initiation of cannabis use and early-onset psychosis. *Substance Abuse, 36*(4), 524-533.
- Barber k. (2018). The Legalization of Marijuana: "Be Prepared". *Journal of Cutaneous Medicine and Surgery, 22*(5), 461-463.
- Bensky, D., & Gamble, A. (1993). *Chinese herbal medicine: Materia medica*. Seattle, WA: Eastland Press.
- Berman, A., & Flannery, M. (2001). *American botanical-medical movements: Vox populi*. New York, NY: Haworth Press.
- Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D., Brandi, I., ... Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *British Journal of Pharmacology, 134*(4), 845-852.
- Blanco, C., Hasin, D.S., Wall, M.M., Flórez-Salamanca, L., Hoertel, N., Wang, S., Kerridge, B.T., & Olfson, M. (2016). Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. *Journal of the American Medical Association Psychiatry, 73*(4). 388-95
- Block, R., Erwin, W., Farinpour, R., & Braverman, K. (1998). Sedative, stimulant, and other subjective effects of marijuana: Relationships to smoking techniques. *Pharmacology Biochemistry and Behavior, 59*(2), 405-412.
- Boden, M.T., Babson, K.A., Vujanovic, A.A., Short, N.A., & Bonn-Miller, M.O. (2013). Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. *American Journal of Addiction, 22*(3), 277-84.
- Bricker, J.B., Russo, J., Stein, M.B., Sherbourne, C., Craske, M., Schraufnagel, T.J., & Roy-Byrne, P. (2007). Does occasional cannabis use impact anxiety and depression treatment outcomes?: Results from a randomized effectiveness trial. *Depression and Anxiety, 24*(6), 392-8.
- Boychuk D.G., Goddard, G., Maurio, G. & Orellana, M.F. (2015). The effectiveness of

cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. *Journal of Oral & Facial Pain and Headache*, 29(1), 7-14.

Brill, N.Q., Crumpton, E., Frank, I.M., Hochman, J.S., Lomax, P., McGlothlin, W.H., & West, L.J. (1970). The marijuana problem. *Annals of Internal Medicine*, 73(3), 449-65.

Buckner, J.D., Ecker, A.H., & Dean, K.E. (2016). Solitary cannabis use frequency mediates the relationship between social anxiety and cannabis use and related problems. *American Journal of Addiction*, 25(2), 99-104.

Cairns, E.A., Baldrige, W.H., & Kelly, M.E. (2016). The Endocannabinoid System as a Therapeutic Target in Glaucoma. *Neural Plasticity*: 9364091. doi: 10.1155/2016/9364091.

Centers for Disease Control and Prevention. (2017). History of the surgeon general's report on smoking and health. Retrieved from https://www.cdc.gov/tobacco/data_statistics/sgr/history/index.htm

Cesamet prescribing information. (2013). Retrieved from http://cesamet.com/pdf/Cesamet_PI_50_count.pdf.

Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., & Crippa, J.A. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. *Journal of Psychopharmacology*, 28(11), 1088-98.

Chang, Z., Bian, Y., He, Q., Yao, J., Zhu, J., Wu, J., ... Duan, T. (2017). Suppression of STAT3 signaling by Δ^9 -tetrahydrocannabinol (THC) induces trophoblast dysfunction. *Cellular Physiology and Biochemistry*, 42(2), 537-550.

Chen, T., He, J., Zhang, J., Zhang, H., Qian, P., Hao, J., & Li, L. (2010). Analytical characterization of hempseed (Seed of *Cannabis sativa* L.) oil from eight regions in China. *Journal of Dietary Supplements*, 7(2), 117-129.

Cho, C.M., Hirsch, R., & Johnstone, S. (2005). General and oral health implications of cannabis use. *Australian Dental Journal*, 50(2):70-4.

- Cotter, J. (2009). Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. *Oncology Nursing Forum*, 1;36(3), 345-352.
- Crippa, J.A., Zuardi, A.W., Martín-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence. *Human Psychopharmacology*, 24(7), 515-23.
- Darling, M.R., & Arendorf, T.M. (1992). Review of the effects of cannabis smoking on oral health. *International Dental Journal*, 42(1), 19-22.
- Darling, M.R., & Arendorf, T.M. (1993). Effects of cannabis smoking on oral soft tissues. *Community Dentistry and Oral Epidemiology*, 21(2), 78-81.
- Deshpande, A., Mailis-Gagnon, A., Zoheiry, N., & Lakha, S.F. (2015). Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. *Canadian Family Physician*, 61(8), e372-81.
- Detyniecki, K., & Hirsch, L. (2015). Marijuana Use in Epilepsy: The Myth and the Reality. *Current Neurology and Neuroscience Reports*, 15(10):65. doi: 10.1007/s11910-015-0586-5.
- Donaldson, M. (2016). Herbal-Drug Interactions Important in Dentistry. West Bridgewater, MA: Western Schools.
- Donaldson, M., Donaldson, D., & Quarnstrom, F. (2012). Nitrous oxide-oxygen administration: when safety features no longer are safe. *J Am Dent Assoc*, 143,134-143.
- Donaldson, M., & Goodchild, J. H. (2012). Pregnancy, breast-feeding and drugs used in dentistry. *J Am Dent Assoc*, 143(8), 858-71.
- Elia, N., Lysakowski, C., & Tramer, M.R. (2005). Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. *Anesthesiology*, 103(6), 1296-1304.
- Epidiolex Prescribing Information. (2018). Retrieved from,

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2103651bl.pdf.

Epilepsy Foundation. (2014). Retrieved from, <https://www.epilepsy.com/>

Etter, J. (2015). Electronic cigarettes and cannabis: An exploratory study. *European Addiction Research, 21*(3), 124-130.

Farnsworth, N., & Soejarto, D. (1991). Global importance of medicinal plants. In O. Akerele, V. Heywood, & H. Synge (Eds.), *The conservation of medicinal plants*. Cambridge, UK: Cambridge University Press.

Fasinu, P., Phillips, S., ElSohly, M., & Walker, L. (2016). Current status and prospects for cannabidiol preparations as new therapeutic agents. *Pharmacotherapy, 36*(7), 781-796.

Felter, H., & Lloyd, J. (1898/1983). *King's American dispensatory* (18th ed.) Sandy, OR: Eclectic Medical Publications.

Firth, N.A. (1997). Marijuana use and oral cancer: a review. *Oral Oncology, 33*(6), 398-401.

Fitzcharles, M.A., Baerwald, C., Ablin, J., & Hauser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. *Schmerz, 30*(1), 47-61.

Foster, D.W., Ecker, A.H., Zvolensky M.J., & Buckner, J.D. (2015). Social anxiety and cannabis cravings: The influences of parent injunctive norms and tension reduction expectancies. *Journal of Social and Clinical Psychology, 34*(9), 731-746.

Friedman, D., & Devinsky, O. (2016). Cannabinoids in the Treatment of Epilepsy. *New England Journal of Medicine, 7*;374(1), 94-5.

Gloss, D., & Vickrey, B. (2014). Cannabinoids for epilepsy. *Cochrane Database of Systematic Reviews, 3*:CD009270. doi: 10.1002/14651858.CD009270.pub3.

Golan, D. (2016). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Fourth ed, Walters Kluwer, 17-27.

González-Ortega, I., Alberich, S., Echeburúa, E., Aizpuru, F., Millán, E., Vieta, E., Matute, C.,

- & González-Pinto, A. (2015). Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. *PLoS One*, *15*;10(4):e0123707.
- Gorelick, D.A., Goodwin, R.S., Schwilke, E., Schroeder, J.R., Schwoppe, D.M., Kelly, D.L., Ortemann-Renon, C., Bonnet, D., & Huestis, M.A. (2013). Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. *American Journal of Addiction*, *22*(5), 510-4.
- Green, K. (1998). Marijuana smoking vs cannabinoids for glaucoma therapy. *Archives of Ophthalmology*, *16*(11), 1433-7.
- Hall, W., & Lynskey, M. (2016). Evaluating the public health impacts of legalizing recreational cannabis use in the United States. *Addiction*, *111*(10), 1764-1773.
- Hasin, D., Sarvet, A., Cerda, M., Keyes, K., Stohl, M., Galea, S., & Wall, M. (2017). US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. *JAMA Psychiatry*, *74*(6), 579-588.
- Hazekamp, A., & Fishedick, J. (2012). Cannabis from cultivar to chemovar. *Drug Testing and Analysis*, *4*(7-8), 660-667.
- Howlett, A.C. (1995). Pharmacology of cannabinoid receptors. *Annual Review of Pharmacology and Toxicology*, *35*, 607-34.
- Institute of Medicine. (1999). *Marijuana and medicine: Assessing the science base*. Washington, DC: National Academies Press.
- Isaac, S., Saini, B., & Chaar, B. (2016). The role of medicinal cannabis in clinical therapy: Pharmacists' perspectives. *PLOS ONE*, *11*(5), e0155113. doi:10.1111/j.1521-0391.2014.12135.x
- Jones, R.T. (2002). Cardiovascular system effects of marijuana. *Journal of Clinical Pharmacology*, *42*, 58S-63S.
- Kedzior, K.K., & Laeber, L.T. (2014). A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31

studies. *BMC Psychiatry*, 14:136

- Kemper, J., Honig, E., & Martin, G. (2015). The effects of marijuana exposure on expiratory airflow: A study of adults who participated in the U.S. National Health and Nutrition Examination Study. *Annals of the American Thoracic Society*, 12(2), 135-141.
- Kendall, D., & Alexander, S. (Eds.). (2017). *Advances in pharmacology: Cannabinoid pharmacology*. Cambridge, MA: Academic Press/Elsevier.
- Kepple, N., & Freisthler, B. (2012). Exploring the ecological association between crime and medical marijuana dispensaries. *Journal of Studies on Alcohol and Drugs*, 73(4), 523-530.
- Kleinig, J. (2015). Ready for retirement: The gateway drug hypothesis. *Substance Use & Misuse*, 50(8-9), 971-975.
- Klotz, K.A., Schulze-Bonhage, A., Antonio-Arce, V.S., & Jacobs, J. (2018). Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey. *Frontiers in Neurology*, 9:731. doi: 10.3389/fneur.2018.00731.
- Koppel, B.S. (2015). Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. *Neurotherapeutics*, 12(4), 788-92.
- Köse, E.O., Deniz, G., Sarikürkçü, C., Aktaş, O. & Yavuz, M. (2010). Chemical composition, antimicrobial and antioxidant activities of the essential oils of *Sideritis erythrantha* Boiss. and Heldr. (var. *erythrantha* and var. *cedretorum* P.H. Davis) endemic in Turkey. *Food and Chemical Toxicology*, 48(10), 2960-5.
- Ksir, C., & Hart, C.L. (2016). Cannabis and Psychosis: a Critical Overview of the Relationship. *Current Psychiatry Reports*, 18(2), 12.
- Lanz, C., Mattsson, J., Soydaner, U., & Brenneisen, R. (2016). Medicinal cannabis: In vitro validation of vaporizers for the smoke-free inhalation of cannabis. *PLOS ONE*, 11(1), e0147286. doi:10.1371/journal.pone.0147286.
- Lee, M. (2012). *Smoke signals: A social history of marijuana – Medical, recreational, and scientific*. New York, NY: Scribner.

- Levin, L. S., & Idler, E. L. (2010). *The hidden health care system*. Neenah, WI: Golden Apple Publications.
- Libster, M. (1999). Guidelines for selecting a medical herbalist for consultation and referral: Consulting a medical herbalist. *Journal of Alternative and Complementary Medicine*, 5(5), 457-462.
- Libster, M. (2002). *Delmar's integrative herb guide for nurses*. Albany, NY: Delmar Thomson Learning.
- Libster, M. (2004). *Herbal diplomats*. Neenah, WI: Golden Apple Publications.
- Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016). From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. *Physiological Reviews*, 96, 1593-1659.
- Lutge, E.E., Gray, A., & Siegfried, N. (2013). The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database of Systematic Reviews*, 30;(4):CD005175.
- Lynch, M.E., & Campbell, F. (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *British Journal of Clinical Pharmacology*, 72(5), 735-44.
- Maloney, W.J. (2011). Significance of cannabis use to dental practice. *New York State Dental Journal*, 77(3), 36-39.
- Marijuana Policy Project. (2017). State policy. Retrieved on February 4, 2018, from <https://www.mpp.org/states/>.
- Marinol prescribing information. (2017). Retrieved from https://www.rxabbvie.com/pdf/marinol_PI.pdf.

- Marks, M.A., Chaturvedi, A.K., Kelsey, K., Straif, K., Berthiller, J., Schwartz, S.M., Smith, E., Wyss, A., Brennan, P., Olshan, A.F., Wei, Q., Sturgis, E.M., Zhang, Z.F., Morgenstern, H., Muscat, J., Lazarus, P., McClean, M., Chen, C., Vaughan, T.L., Wunsch-Filho, V., Curado, M.P., Koifman, S., Matos, E., Menezes, A., Daudt, A.W., Fernandez, L., Posner, M., Boffetta, P., Lee, Y.C., Hashibe, M., & D'Souza, G (2014). Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. *Cancer Epidemiology Biomarkers and Prevention*, 23(1), 160-71
- Mathias, T. GW Pharma cannabis drug set to hit market following DEA nod. (2018). Retrieved from, <https://www.reuters.com/article/us-gw-pharma-dea/gw-pharma-cannabis-drug-set-to-hit-market-following-dea-nod-idUSKCN1M71WI>.
- McKenna, T. (1992). *Food of the gods: The search for the original tree of knowledge – A radical history of plants, drugs, and human evolution*. New York, NY: Bantam.
- McLaren, J., Swift, W., Dillon, P., & Allsop, S. (2008). Cannabis potency and contamination: A review of the literature. *Addiction*, 103(7), 1100-1109.
- McLoughlin, B.C., Pushpa-Rajah, J.A., Gillies, D., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014). Cannabis and schizophrenia. *Cochrane Database Systematic Reviews*, 10:CD004837.
- Miech, R., Patrick, M., O'Malley, P., & Johnston, L. (2017). The influence of college attendance on risk for marijuana initiation in the United States: 1977 to 2015. *American Journal of Public Health*, 107(6), 996-1002.
- Mikulcová, V., Kašpárková, V., Humpolíček, P., & Buňková, L. (2017). Formulation, Characterization and Properties of Hemp Seed Oil and Its Emulsions. *Molecules*, 22(5). pii: E700.
- Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B., & Muller, J. E. (2001).

Triggering myocardial infarction by marijuana. *Circulation*, 103, 2805-2809.

Moerman, D. (1998). *Native American ethnobotany*. Portland, OR: Timber Press.

Moitra, E., Anderson, B.J. & Stein, M.D. (2016). Reductions in cannabis use are associated with mood improvement in female emerging adults. *Depression and Anxiety*, 33(4), 332-8.

Moore, P.A., & Hersh, E.V. (2013). Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions: translating clinical research to dental practice. *Journal of the American Dental Association*, 144(8), 898-908.

Nadkarni, K. (1976). *Indian materia medica*. New Delhi, India: Mehra Offset Press.

Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., & Konikoff, F.M. (2013). Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clinical Gastroenterology and Hepatology*, 11(10), 1276-1280.

National Academies of Science, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: National Academies Press. Retrieved from <https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state>.

National Cancer Institute. (2017). Cannabis and cannabinoids (PDQ®) – Health professional version. Retrieved from https://www.cancer.gov/aboutcancer/treatment/cam/hp/cannabis-pdq#section/_9

National Conference of State Legislatures. (2017). Marijuana overview. Retrieved from <http://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx>

National Institute on Drug Abuse (2017e). Is marijuana a gateway drug? Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/marijuana-gateway-drug>

- National Institute on Drug Abuse. (2016). Marijuana: Facts parents need to know – Starting the conversation. Retrieved from <https://www.drugabuse.gov/publications/marijuana-facts-parents-need-to-know/starting-conversation>
- National Institute on Drug Abuse. (2016). Synthetic cannabinoids (K2/Spice). Retrieved from <https://www.drugabuse.gov/drugs-abuse/synthetic-cannabinoids-k2spice>
- National Institute on Drug Abuse. (2017a). Available treatments for marijuana use disorders. Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/available-treatments-marijuana-use-disorders>
- National Institute on Drug Abuse. (2017a). Can marijuana use during and after pregnancy harm the baby? Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/can-marijuana-use-during-pregnancy-harm-baby>
- National Institute on Drug Abuse. (2017b). Drug facts – What is marijuana? Retrieved from <https://www.drugabuse.gov/publications/drugfacts/marijuana>
- National Institute on Drug Abuse. (2017b). Is marijuana safe and effective as medicine? Retrieved from <https://www.drugabuse.gov/publications/marijuana/marijuana-safe-effective-medicine>
- National Institute on Drug Abuse. (2017c). How does marijuana produce its effects? Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/how-does-marijuana-produce-its-effects>
- National Institute on Drug Abuse. (2017c). What is marijuana? Retrieved from <https://www.drugabuse.gov/publications/drugfacts/marijuanaMedMariChap1Format.docx>
- National Institute on Drug Abuse. (2017d). Is marijuana addictive? Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana/marijuana-addictive>
- Norberg, M., Olivier, J., Schmidt, N., & Zvolensky, M. (2014). Cannabis use among treatment-seeking smokers: Motives and the moderating effects of anxiety sensitivity.

The American Journal on Addictions, 23(1), 7-14.

- Núñez, C., Ochoa, S., Huerta-Ramos, E., Baños, I., Barajas, A., Dolz, M., Sánchez, B., Del Cacho, N.; GENIPE Group, & Usall, J. (2016). Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use. *Psychopharmacology (Berlin)*, 233(5), 809-21.
- O'Connell, B.K., Gloss, D., & Devinsky, O. (2017). Cannabinoids in treatment-resistant epilepsy: A review. *Epilepsy and Behaviour*, 70(Pt B), 341-348
- O'Connor, B. (1995). *Healing traditions: Alternative medicine and the health professions*. Philadelphia, PA: University of Pennsylvania Press.
- Ogeil, R.P., Phillips, J.G., Rajaratnam, S.M., & Broadbear, J.H. (2015). Risky drug use and effects on sleep quality and daytime sleepiness. *Human Psychopharmacology*, 30(5), 356-63.
- Orem, D., Renpenning, K., & Taylor, S. (2003). *Self-care theory in nursing*. New York, NY: Springer Publishing Company.
- Peters, E., Budney, A., & Carroll, K. (2012). Clinical correlates of co-occurring cannabis and tobacco use: A systematic review. *Addiction*, 107(8), 1404-1417.
- Phillips, R.N., Turk, R.F., & Forney, R.B. (1971). Acute toxicity of delta-9-tetrahydrocannabinol in rats and mice. *Proceedings of the Society of Experimental Biology and Medicine*, 136(1), 260-3.
- Piontek, D., Kraus, L., & Klempova, D. (2008). Short scales to assess cannabis-related problems: A review of psychometric properties. *Substance Abuse Treatment, Prevention, and Policy*, 3(25). doi:10.1186/1747-597X-3-25.
- Porcella, A., Maxia, C., Gessa, G.L., & Pani, L. (2001). The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. *The European Journal of Neuroscience*, 13(2), 409-12.
- Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S.,

McQuade, R., Wright, S., & Fallon, M.T. (2012). Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *Journal of Pain, 13*(5), 438-49.

Prescribers' Digital Reference. (2018). Dronabinol drug summary. Retrieved from <http://www.pdr.net/drug-summary/Marinol-dronabinol-2726.4113>.

Pushpa-Rajah, J.A., McLoughlin, B.C., Gillies, D., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2015). Cannabis and schizophrenia. *Schizophrenia Bulletin, 41*(2), 336-7.

Ramer, R., & Hinz, B. (2008). Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. *Journal of the National Cancer Institute, 100*(1), 59-69.

Reis, J., Auer, R., Bancks, M., Goff, D., Lewis, C., Pletcher, M., ... & Sidney, S. (2017). Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: The coronary artery risk development in young adults (CARDIA) study. *American Journal of Public Health, 107*(4), 601-606.

Ribeiro, L., & Ind, P. (2016). Effect of cannabis smoking on lung function and respiratory symptoms: A structured literature review. *Primary Care Respiratory Medicine, 26*, 16071. doi:10.1038/npj-crm.2016.71

Rosenberg, M. (2010). Preparing for medical emergencies: the essential drugs and equipment for the dental office. *Journal of the American Dental Association, 141*(Suppl 1), 14S-19S.

Russo, E. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology, 163*(7), 1344-1364.

Russo, E. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. *Cannabis and Cannabinoid Research, 1*(1), 154-165.

Sativex prescribing information. (2015). Retrieved from

<https://www.bayer.ca/omr/online/sativex-pm-en.pdf>.

Schaffer Library on Drug Policy. (2018). What is the lethal dose of marijuana? Retrieved from http://www.druglibrary.org/SCHAFFER/LIBRARY/mj_overdose.htm.

Schepker, K. (2017, Spring). In cannabis-friendly states, opioid overdoses decline. *Holistic Primary Care*, 11.

Schoeler, T., Petros, N., Di Forti, M., Pingault, J.B., Klamerus, E., Foglia, E., Small, A., Murray, R., & Bhattacharyya, S. (2016). Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study. *Journal of the American Medical Association Psychiatry*, 73(11), 1173-1179.

Selvarajah, D., Ghandi, R., Emery, C.J., & Tesgaye, S. (2010). Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. *Diabetes Care*, 33(1), 128-30.

Smeriglio, A., Galati, E., Monforte, M., Lanuzza, F., Angelo, V., & Circosta, C. (2016). Polyphenolic compounds and antioxidant activity of cold-pressed seed oil from Finola cultivar of *Cannabis sativa* L. *Phytotherapy Research*, 30(8), 1298-1307.

Soltész, I., Alger, B.E., Kano, M., Lee, S.H., Lovinger, D.M., Ohno-Shosaku, T., & Watanabe, M. (2015). Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. *Nature Reviews. Neuroscience*, 16(5), 264-77.

Steenkamp, M.M., Blessing, E.M., Galatzer-Levy, I.R., Hollahan, L.C., & Anderson, W.T. (2017). Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. *Depression and Anxiety*, 34(3), 207-216

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2015). *Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50)*. Retrieved from

<https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm#idtextanchor009>.

Tan, W.C., Lo, C., Jong, A., Xing, L., Fitzgerald, M.J., Vollmer, W.M., Buist, S.A., & Sin, D.D.; Vancouver Burden of Obstructive Lung Disease (BOLD) Research Group. (2009). Marijuana and chronic obstructive lung disease: a population-based study. *Canadian Medical Association Journal*, 180(8), 814-20.

Tashkin, D. (2015). How beneficial is vaping cannabis to respiratory health compared to smoking? *Addiction*, 110(11), 1706-1707.

Tashkin, D.P. (2018). Marijuana and lung disease. *Chest*, 154(3), 653-663.

The Linnean Society (2018). Who was Linnaeus? Retrieved from <https://www.linnean.org/education-resources/who-was-linnaeus>.

Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *British Journal of Pharmacology*, 150(5), 613-623.

Thomas, G., Kloner, R., & Rezkalla, S. (2014). Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: What cardiologists need to know. *American Journal of Cardiology*, 113(1), 187-190.

Tompkins, P., & Bird, C. (1973). *The secret life of plants*. New York, NY: Harper & Row.

Touw, M. (1981). The religious and medicinal uses of cannabis in China, India, and Tibet. *Journal of Psychoactive Drugs*, 13(1), 23-24.

Tzadok, M., Uliel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, S., Nissenkorn, A., Yosef, O.B., Hyman, E., Granot, D., Dor, M., Lerman-Sagie, T., & Ben-Zeev, B. (2016). CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. *Seizure*, 35, 41-4.

U.S. Department of Health and Human Services. (2017). HHS acting secretary declares public

health emergency to address national opioid crisis. Retrieved from <https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html>.

U.S. Drug Enforcement Administration. (2016, August 11). *DEA announces actions related to marijuana and industrial hemp*. Retrieved from <https://www.dea.gov/divisions/hq/2016/hq081116.shtml>.

U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. Retrieved on February 4, 2018, from <https://www.dea.gov/druginfo/ds.shtml>.

United Nations Office on Drugs and Crime (2017b). *World drug report: Executive summary*. Vienna, Austria: United Nations Publication. Retrieved from https://www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf

United Nations Office on Drugs and Crime. (2017a). *Market analysis of plant-based drugs: Opiates, cocaine, and cannabis*. Retrieved from https://www.unodc.org/wdr2017/field/Booklet_3_Plantbased.pdf

Vandrey, R., & Haney, M. (2009). Pharmacotherapy for cannabis dependence: How close are we? *CNS Drugs*, 23(7), 543-553.

Vorspan ,F., Mehtelli, W., Dupuy, G., Bloch, V., & Lépine, J.P. (2015) Anxiety and substance use disorders: co-occurrence and clinical issues. *Curr Psychiatry Rep*, 17(2), 4.

Weed, S. (1986). *Wise woman herbal for the childbearing year*. New York, NY: Ash Tree Publishing.

Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., Schmidtkofer, S., Westwood, M., & Kleijnen, J. (2015) .Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *Journal of the American Medical Association*, 313(24), 2456-73.

World Health Organization. (2013). *WHO traditional medicine strategy, 2014-2023*. Geneva, Switzerland: Author. Retrieved from http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/

- Yadav, V., Bever, C. Jr., Bowen, J., Bowling, A., Weinstock-Guttman, B., Cameron, M., Bourdette, D., Gronseth, G.S., & Narayanaswami, P. (2014). Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*, 25;82(12), 1083-92.
- Zhang, Z., Morgenstern, H., Spitz, M.R., Tashkin, D.P., Yu, G.P., Marshall, J.R., Hsu, T.C., & Schantz, S.P. (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiology Biomarkers and Prevention*, 8(12), 1071-1078.
- Zorrilla, I., Aguado, J., Haro, J.M., Barbeito, S., López Zurbano, S., Ortiz, A., López, P., & Gonzalez-Pinto, A. (2015). Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? *Acta Psychiatrica Scandinavica*, 131(2). 100-10.